Summary
Insulin is a peptide hormone essential for glucose metabolism, widely used as a therapeutic for diabetes mellitus. Fast-acting insulin analogs are designed to limit hexamer formation, favoring monomeric or dimeric states that facilitate rapid absorption into the bloodstream. Consistency in this structural organization is critical for achieving predictable pharmacokinetics.
This application note demonstrates SAXS characterization of a commercial fast-acting insulin formulation to control molecular organization. Despite modifications intended to enhance monomer stability, the PDDF analysis reveals the presence of oligomers, providing important quality control information for these pharmaceutical formulations.
Background & Challenge
Insulin Structure & Oligomerization
Human insulin (5.8 kDa monomer) consists of two polypeptide chains:
- A-chain: 21 amino acids
- B-chain: 30 amino acids
- Disulfide bonds: Two inter-chain and one intra-chain bond
In solution, insulin forms concentration-dependent oligomers:
- Monomer: ~6 kDa (dilute solution, low pH)
- Dimer: ~12 kDa (equilibrium form)
- Hexamer: ~36 kDa (stabilized by Zn2+, phenolic compounds)
Pharmaceutical Relevance
- Storage stability: Hexamers provide long-term stability in formulation
- Injection depot: Hexamers dissociate slowly after subcutaneous injection
- Pharmacokinetics: Dissociation to monomers controls absorption rate
- Formulation design: Rapid vs. long-acting insulins differ in oligomerization
Methods & Experimental Design
Sample Information
Sample: Fast-acting insulin formulation
Concentration: 3.5 mg/mL
SAXS Measurement
Instrument Parameters
- X-ray sourceCu Kα
- InstrumentLaboratory SAXS at DANNALAB
- Q range0.05-4.3 nm⁻¹
SAXS Reconstruction of PDDF Function
Structural Parameters
Radius of Gyration
Rg = 2.0 ± 0.2 nm
From PDDF analysis
Formulation
3.5 mg/mL
Commercial batch
Oligomerization
Oligomers present
Despite fast-acting design
PDDF Function
Determined
Structural fingerprint obtained
Figure 1. Pair Distance Distribution Function (PDDF) of fast-acting insulin formulation (3.5 mg/mL). Rg = 2.0 ± 0.2 nm suggests presence of oligomers despite modifications intended to enhance monomer stability.
The PDDF function was reconstructed from the SAXS data. The determined radius of gyration (Rg) of 2.0 ± 0.2 nm suggests the presence of oligomers, despite the modifications intended to enhance monomer stability in fast-acting insulin formulations.
Conclusion
SAXS characterization of commercial fast-acting insulin batches provides insights into the molecular-level organization of insulin formulations. This structural information is useful for quality control of insulin formulations, where consistency in molecular organization is critical for achieving predictable pharmacokinetics.